ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0406

Infliximab in Refractory Uveitis Due to Behçet’s Disease: Long Term Follow-up and Therapy Optimization. Multicenter Study of 103 Caucasian Patients

José Luis Martín-Varillas1, Belén Atienza-Mateo2, Vanesa Calvo-Río3, Emma Beltran-Catalan4, Alfredo Adan5, Marisa Hernandez Garfella6, Elia Valls-Pascual7, Agustín Sellas-Fernández8, N Ortego9, Alejandro Fonollosa10, Olga Maiz Alonso11, Ignacio Torre12, Cruz Fernández-Espartero13, Vega Jovani14, Diana Peiteado15, David Díaz Valle16, Susana Romero-Yuste17, Elena Aurrecoechea1, Miriam García-Arias18, Miguel Ángel Caracuel19, Santos Insúa20, Senén González-Suárez21, Amalia Sánchez Andrade22, Luis Francisco Linares23, Alfredo J García González24, Raquel Almodovar25, Carmen Carrasco Cubero26, María Alcalde Villar27, C Fernandez-Carballido28, Fred A Pages29, Eva Peña Sainz-Pardo24, Rosalia Demetrio-Pablo3, Santos Castañeda30, Miguel Ángel González-Gay31, José Luis Hernández3 and Ricardo Blanco3, 1Hospital Sierrallana, Torrelavega, Spain, 2Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Hospital Universitario Marques de Valdecilla, Santander, Spain, 4Del Mar University Hospital, Barcelona, 5Hospital Clinic, Barcelona, Catalonia, Spain, 6H. Valencia, Valencia, Spain, 7H. Doctor Peset, Valencia, Spain, 8H. Vall d'Hebron, Barcelona, Spain, 9H. San Cecilio, Granada, Spain, 10H. de Cruces, Bilbao, Spain, 11Hospital Universitario Donostia, San Sebastian, Pais Vasco, Spain, 12Hospital Basurto, Bilbao, Spain, 13H. Mostoles, Madrid, Spain, 14H. Alicante, Alicante, Spain, 15Hospital La Paz - IdiPAZ, Madrid, Spain, 16H. Clínico San Carlos, Madrid, Spain, 17H Pontevedra, Coruna, Spain, 18H. La Princesa, Madrid, 19H.U. Reina Sofía, Córdoba, Spain, 20H. Santiago de Compostela, Santiago de Compostela, Spain, 21H. Cabueñes, Gijón, Spain, 22H. Lucus Augusti, Lugo, Spain, 23Hospital de la Arrixaca, Murcia, 24H. 12 de Octubre, Madrid, Spain, 25Fundación Alcorcón University Hospital, Madrid, 26H. Mérida, Mérida, Spain, 27H. Severo Ochoa, Madrid, Spain, 28H San Juan, Alicante, Spain, 29H. Palencia, Palencia, Spain, 30Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, 31Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

Meeting: ACR Convergence 2020

Keywords: Anti-TNF Drugs, Behçet's Syndrome, Eye Disorders, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Biologic therapy has improved prognosis of Behçet Disease (BD) uveitis. Although infliximab (IFX) is approved in Japan, most data in Caucasian patients comes from small series and no data on IFX optimization has been published. In the present study we assessed: a) long-term efficacy and safety of IFX and b) IFX optimization when ocular remission was achieved

Methods: Multicenter study of IFX-treated patients with BD uveitis refractory to conventional immunosuppressants.103 patients were treated with IFX as 1st biologic as follows: 3-5 mg/kg i.v. at 0, 2, 6 and every 4-8 weeks. The main outcomes were anterior chamber cells, vitritis, retinal vasculitis, macular thickness, best corrected visual acuity, and the glucocorticoids sparing effect that were analysed at baseline, 1st week, 1st and 6th months and 1st and 2nd years. After remission, based on a shared decision between patient and clinician, IFX optimization was performed. Efficacy, safety, and IFX cost were evaluated

Results: In whole series (n=103), main outcomes showed a rapid and maintained improvement, reaching remission in 78 patients after a mean IFX duration of 31.5 months. Severe side-effects were observed in 9 patients.

In the optimization subanalysis, comparative study between optimized and non-optimized groups showed: a) no differences in clinical baseline characteristics; b) similar maintained improvement in most ocular outcomes; c) lower severe adverse events and d) lower IFX cost in optimized group (4826.52 vs. 9854.13 euros/patient/year) (Table)

Conclusion: IFX seems effective and relatively safe in Caucasian patients with refractory BD uveitis. IFX optimization is also effective, safe, and cost-effective

Main general features and follow-up of a subgroup of patients (n= 60) with Refractory Uveitis Due to BD who Achieved Remission after the standard dose of IFX therapy (5 mg/kg at 0, 2, 6 and then every 8 weeks). Differences between Optimized and Non-optimized patients


Disclosure: J. Martín-Varillas, None; B. Atienza-Mateo, None; V. Calvo-Río, None; E. Beltran-Catalan, None; A. Adan, None; M. Hernandez Garfella, None; E. Valls-Pascual, None; A. Sellas-Fernández, None; N. Ortego, None; A. Fonollosa, None; O. Maiz Alonso, Novartis, 1; I. Torre, None; C. Fernández-Espartero, None; V. Jovani, None; D. Peiteado, None; D. Díaz Valle, None; S. Romero-Yuste, None; E. Aurrecoechea, None; M. García-Arias, None; M. Caracuel, None; S. Insúa, None; S. González-Suárez, None; A. Sánchez Andrade, None; L. Linares, None; A. García González, None; R. Almodovar, None; C. Carrasco Cubero, None; M. Alcalde Villar, None; C. Fernandez-Carballido, None; F. Pages, None; E. Peña Sainz-Pardo, None; R. Demetrio-Pablo, None; S. Castañeda, Roche, 2; M. González-Gay, None; J. Hernández, None; R. Blanco, None.

To cite this abstract in AMA style:

Martín-Varillas J, Atienza-Mateo B, Calvo-Río V, Beltran-Catalan E, Adan A, Hernandez Garfella M, Valls-Pascual E, Sellas-Fernández A, Ortego N, Fonollosa A, Maiz Alonso O, Torre I, Fernández-Espartero C, Jovani V, Peiteado D, Díaz Valle D, Romero-Yuste S, Aurrecoechea E, García-Arias M, Caracuel M, Insúa S, González-Suárez S, Sánchez Andrade A, Linares L, García González A, Almodovar R, Carrasco Cubero C, Alcalde Villar M, Fernandez-Carballido C, Pages F, Peña Sainz-Pardo E, Demetrio-Pablo R, Castañeda S, González-Gay M, Hernández J, Blanco R. Infliximab in Refractory Uveitis Due to Behçet’s Disease: Long Term Follow-up and Therapy Optimization. Multicenter Study of 103 Caucasian Patients [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/infliximab-in-refractory-uveitis-due-to-behcets-disease-long-term-follow-up-and-therapy-optimization-multicenter-study-of-103-caucasian-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/infliximab-in-refractory-uveitis-due-to-behcets-disease-long-term-follow-up-and-therapy-optimization-multicenter-study-of-103-caucasian-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology